WHO WE ARE
Oncogenome is Precision Oncology
Oncology is the specialized branch of medicine that deals with the study and treatment of tumors.
Cancer can now be considered a genetic disease, characterized by uncontrolled cell growth. Genetic predisposition testing is intended for individuals who, based on a thorough family history, have a high and specific incidence of neoplastic diseases in previous generations and are therefore at increased risk of carrying germline mutations.
The information obtained from genetic testing can provide numerous benefits, including:
identifying family members at high risk of developing cancer; planning an appropriate medical screening program for at-risk individuals, in order to promote early diagnosis at the onset of the disease;
awareness of the possibility of transmitting genetic mutations to offspring and the identification of children potentially at risk;
the evaluation of any indications for preventive prophylaxis interventions.
Our Committee
The field of precision medicine is rapidly evolving, offering an ever-expanding range of therapies for patients with specific genetic mutations. Our Molecular Oncology Committee, through NGS sequencing of tumor samples, enables us to explore the most advanced therapeutic options.
We have a multidisciplinary team that includes medical oncologists, genetic counselors, pathologists, hematologists, and molecular specialists who meet and propose a treatment plan that takes into account the mutations and characteristics of the disease, defining a comprehensive treatment plan.
This approach allows us to achieve better outcomes in the treatments of our patients and also allows us to build the building blocks of tomorrow's medicine.
Oncogenoma is not a hospitalization and treatment facility, it does not prescribe drugs, but we establish a close collaboration with the oncology department that is treating the patient.
Scientific Director: Dr. P. Adilardi
Members of the Molecular Oncology Committee
- Oncology Specialists
- Experts in Molecular Profiling
- Genetic Researchers
- Anatomopathology
- Patient treatment team
NGS technology seeks precise diagnoses to improve treatments and the quality of life of people affected by various diseases.
NGS (Next-Generation Sequencing) in oncology is a next-generation sequencing technology that rapidly analyzes a tumor's DNA or RNA to identify genetic mutations. This allows for personalized treatment through so-called precision oncology, choosing therapies targeted to a patient's specific genetic alterations. NGS is used for both somatic mutations (present in the tumor) and inherited cancer predisposition syndromes.
How it works
· Rapid sequencing: NGS analyzes a large number of genes, or even the entire genome, simultaneously, unlike traditional methods.
· Mutation identification: The technology detects specific genetic mutations present in the tumor DNA or in the patient's germline (inherited).
· Data Analysis: After sequencing, software analyzes the data to provide a result that includes significant genetic variants.
Applications of NGS in cancer
- Tumor diagnosis and profiling
- Identify driver mutations (e.g., EGFR, KRAS, BRAF, TP53).
- It helps to classify tumor types and subtypes more accurately.
- Selection of targeted therapy
- Find actionable mutations that guide treatment, for example,
- EGFR Mutations → EGFR Inhibitors
- ALK fusions → ALK inhibitors
- BRCA1/2 mutations → PARP inhibitors
- Predicting response to immunotherapy
- Assess tumor mutational burden (TMB) or microsatellite instability (MSI) to predict response to immune checkpoint inhibitors.
- Minimal residual disease (MRD) and monitoring
- Detects circulating tumor DNA (ctDNA) in the blood, for early diagnosis of relapses or treatment monitoring.
- Tests for hereditary cancer
- It identifies germline mutations in genes such as BRCA1, BRCA2, TP53, MLH1, etc., to assess inherited cancer risk.